Adjuvant effect of Bacillus firmus on the expression of cytokines and toll-like receptors in mouse nasopharynx-associated lymphoid tissue (NALT) after intranasal immunization with inactivated influenza virus type A
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
20709105
DOI
10.1016/j.imlet.2010.08.006
PII: S0165-2478(10)00200-2
Knihovny.cz E-resources
- MeSH
- Adjuvants, Immunologic administration & dosage MeSH
- Principal Component Analysis MeSH
- Administration, Intranasal MeSH
- Bacillus immunology MeSH
- Time Factors MeSH
- Cytokines genetics MeSH
- Gene Expression drug effects MeSH
- Immunization methods MeSH
- Interferon Type I genetics MeSH
- Interleukin-10 genetics MeSH
- Interleukin-2 genetics MeSH
- Lymphoid Tissue metabolism MeSH
- Membrane Glycoproteins genetics MeSH
- Mice, Inbred BALB C MeSH
- Mice MeSH
- Nasopharynx metabolism MeSH
- Reverse Transcriptase Polymerase Chain Reaction MeSH
- Drug Synergism MeSH
- Toll-Like Receptor 2 genetics MeSH
- Toll-Like Receptor 3 genetics MeSH
- Toll-Like Receptor 7 genetics MeSH
- Toll-Like Receptor 9 genetics MeSH
- Toll-Like Receptors genetics MeSH
- Influenza Vaccines administration & dosage immunology MeSH
- Influenza A Virus, H1N1 Subtype immunology MeSH
- Animals MeSH
- Check Tag
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Adjuvants, Immunologic MeSH
- Cytokines MeSH
- Interferon Type I MeSH
- Interleukin-10 MeSH
- Interleukin-2 MeSH
- Membrane Glycoproteins MeSH
- Tlr2 protein, mouse MeSH Browser
- TLR3 protein, mouse MeSH Browser
- Tlr7 protein, mouse MeSH Browser
- Toll-Like Receptor 2 MeSH
- Toll-Like Receptor 3 MeSH
- Toll-Like Receptor 7 MeSH
- Toll-Like Receptor 9 MeSH
- Toll-Like Receptors MeSH
- Influenza Vaccines MeSH
Due to the persisting threat of development of new highly pathogenic influenza A subtypes, a mucosal vaccination which would induce a potent and cross-protective reaction is desirable. We succeeded in mucosal immunization of mice with an inactivated influenza A virus by using delipidated Bacillus firmus (DBF) as adjuvant. The mechanism of adjuvant effect was followed in NALT by comparing the response after intranasal immunization by inactivated influenza virus type A (H1N1) alone, adjuvant alone (DBF), or by a mixture of virus+DBF. Expression of selected gene groups was tested via qPCR at 7 different time-points: cytokines (IL-2, IFN-γ, IL-4, IL-6, and IL-10), type I interferons (IFN-α4, IFN-α11, IFN-α12, and IFN-β), toll-like receptors (TLR2, TLR3, TLR7, and TLR9), iNOS and CCR7. Intranasally administered DBF and the mixture of virus+DBF induced an elevated expression of IFN-γ, IL-6 and IL-10 cytokines, type I interferons, iNOS, and pDC markers in NALT. Multimarker qPCR data was analyzed by relative quantification and by principal component analysis. DBF has been shown to be a very efficient adjuvant for the stimulation of innate immunity after IN immunization. DBF accelerated, increased, and prolonged the antiviral response.
References provided by Crossref.org
Immunomodulatory properties of subcellular fractions of a G+ bacterium, Bacillus firmus
